Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$250.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Angiodynamics Inc Reiterates FY 2013 Guidance-Conference Call


Thursday, 13 Sep 2012 02:24pm EDT 

Angiodynamics Inc reiterated the guidance that laid out in fourth-quarter earnings conference call unchanged. The Company believes topline will grow 5% in fiscal 2013 from the pro forma last year and will exit the year with a high single-digit rate of growth of revenues, Operating income $34 million to $36 million on a non-GAAP basis and excluding all of the acquisition effects of course. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $360 million, and operating profit of $34 million for fiscal 2013. 

Company Quote

10.68
0.0 +0.00%
20 May 2013